Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir by Quarter
Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir: $3M in Q3 2020, down 66.7% from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2020 figure comes from
Source: Form 10-Q (filed 2020-11-04) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2020 | Sep 30, 2020 | 3 | -66.7% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 6 | -14.3% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 4 | +100.0% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 7 | +250.0% | Form 10-K (filed 2020-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 9 | +125.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 7 | +133.3% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 2 | -60.0% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 2 | -33.3% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 4 | +300.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 3 | – | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 5 | – | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 3 | -25.0% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 1 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 0 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 0 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 4 | – | Form 8-K (gildq42017exh991.htm, filed 2018-02-06) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir ($M), quarterly Q4 2016–Q3 2020 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-vosevi-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.